Project Description


CEO: Paul Goode

Sector: Medtech, Gastrointestinal
Location: Texas, USA / Nijmegen, Netherlands
Investment Stage: Early
Investment Status: Liquidated
Year Invested: 2016

EndoStim is a medical device company based in Dallas, Texas, and Nijmegen, The Netherlands, developing and commercializing a revolutionary treatment for gastroesophageal reflux disease (GERD). EndoStim’s neurostimulation technology is designed to provide long-term reflux control by restoring normal oesophageal function. The therapy directly targets the patient’s weak or dysfunctional lower oesophageal sphincter (LES) muscle between the stomach and the oesophagus, often the underlying cause of reflux. The system consists of an implantable neurostimulator and a lead that delivers low energy stimulation to the LES. The EndoStim procedure is designed to preserve natural anatomy in order to reduce or avoid typical gastrointestinal side effects of traditional anti-reflux surgery.

See Endostim related news here

Back to all companies

Endeavour Vision
Board Member

Alexander Schmitz

Endeavour Vision
Deal Team

Robert O'Holla

Robert O’Holla

Damien Tappy

Damien Tappy